Clinical and immunological effects of cooling in multiple sclerosis

Neurorehabilitation and Neural Repair

Volumn 10, Issue 1, 1996, Pages 9-15

  Coyle, P K ^a   Krupp, L B ^a   Doscher, Carol ^a   Deng, Zhidian ^a   Milazzo, Anthony ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Cooling; Cytokine; Multiple sclerosis

Indexed keywords

EID: 21344474051     PISSN: 15459683     EISSN: 15526844     Source Type: Journal    
DOI: 10.1177/154596839601000102     Document Type: Article

References (40)

1. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992; 31:333-36.
2. Weinshenker BG, Bass B., Rice Gpa,et al.The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-46.
3. Minden SL, Marder WD, Harrold LN, Dor A. Multiple sclérosis. A statistical portrait: a compendium of data on demographics, disability, and health service utilization in the United States. Cam-bridge, MA: Abt. Associates, 1993.
4. Waksman BH Multiple sclerosis: more genes versus environment. Nature 1995;377:105-106.
5. Jacobs L., Cookfair D., Rudick R.,et al.Results of a phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis (abstr). Ann Neurol 1994;36:259.
6. Johnson KP, Brooks BR, Cohen JA,et al.Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1994;45:1268-76.
7. The Ifnb Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
8. Guthrie TC Visual and motor changes in patients with multiple sclerosis. A result of induced changes in environmental temperature. Arch Neurol Psychiatry 1951;65:437-51.
9. Davis FA, Michael JA, Tomaszewski JS, Fluctuations in multiple sclerosis related to circadian temperature variations. Dis Nerv Sys 1973;34:33-36.
10. Nelson DA, Jeffreys WH, McDowell F. Effects of induced hyperthermia in some neurological diseases. Arch Neurol Psychiatry 1958;79:31-39.
11. Nelson DA, Jeffreys WH, McDowell F. Effects of induced hyperthermia on patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1959;22:113-16.
12. Davis FA, Michael JA, Neer D. Serial hyperthermia testing in multiple sclerosis: a method of monitoring subclinical fluctuations. Acta Neurol Scand 1973;49:63-74.
13. Michael JA, Davis FA Effects of induced hyperthermia in multiple sclerosis: differences in visual acuity during heating and recovery phases. Acta Neurol Scand 1973;49(S2):141-51.
14. Berger JR, Sheremata WA Persistent neurological deficit precipitated by the hot bath test. JAMA 1983;249:1751-53.
15. Thompson DS Blurring of vision in exercise. Trans Ophthalmol Soc UK 1966;86:479-92.
16. Perkin GD, Rose FC Uhtoff's symptom. Brit J Ophthal 1976; 60:60-63.
17. Van Diemen HAM, Van Dongen MM, Dammers JWHH, Polman CH. Increased visual impairment after exercise (Uhtoff's phenomenon) in multiple sclerosis: therapeutic possibilities. Eur Neurol 1992;32:231-34.
18. Krupp LB Alvarez LA, LaRocca NG, Scheinberg LC Fatigue in multiple sclerosis. Arch Neurol 1988;45:435-37.
19. Watson CW Effect of lowering body temperature on the symptoms and signs of multiple sclerosis. New Engl J Med 1959; 261:1253-59.
20. Hopper CL, Matthew CG, Cleeland CS Symptom instability and thermoregulation in multiple sclerosis. Neurology 1972; 22:142-48.
21. Geller M. Appearance of signs and symptoms of multiple sclerosis in response to cold. Mt. Sinai J Med 1974;41:127-30.
22. Scherokman BT, Selhorst JB, Waybright EA, Jabbari B, Bryan GE, Maitland CG. Improved optic nerve conduction with ingestion of ice water. Ann Neurol 1985;17:418-19.
23. PoserCM, Paty DW, Scheinberg L.,et al.New diagnostic criteria for multiple sclerosis: guidelines for research proposals. Ann Neurol 1983;13:227-31.
24. Fotino M., Merson EJ, Allen FH Micromethod for rapid separation of lymphocytes from peripheral blood. Ann Clin Lab Sci 1971;1:131-33.
25. Syndulko K., Woldanski A, Baumhefner RW, Tourtellotte WW. Acute effects of cooling in multiple sclerosis: pilot study to compare two cooling garments (abstr). Neurology 1995; 45(S4):A351.
26. Geisler MW, Gaudino EA, Squires NK, Coyle PK, Krupp LB. Cooling and multiple sclerosis: cognitive and sensory effects. J Neuro Rehab 1996;10:17-22.
27. Rasminsky M. The effects of temperature on conduction in demyelinated single nerve fibers. Arch Neurol 1973;28:287-92.
28. Schauf CL, Davis FA Impulse conduction in multiple sclerosis: a theoretical basis for modification by temperature and pharmacological agents. J Neurol Neurosurg Psychiatry 1974;37: 152-61.
29. Lederman HM, Brill CR Murphy P. Interleukin 1-driven secretion of interleukin 2 is highly temperature sensitive. J Immunol 1987;138:3808-11.
30. Haeffner-Cavaillon N., Roussellier N., Ponzio O.,et al.Induction of interleukin-1 production in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989;98:1100-1106.
31. Menasche P., Haydar S., Peynet J.,et al.A potential mechanism of vasodilation after warm heart surgery. The temperature dependent release of cytokines. J Thorac Cardiovasc Surg 1994;107:292-99.
32. Pober JS Cytokine-mediated activation of vascular endothelium. Am J Pathol 1988;133:426-33.
33. Dinarello CA Interleukin-1 and its biological related cytokines. Adv Immunol 1989;44:153-203.
34. Quagliarello VJ, Wispelwey B., Long WJ Jr, Scheld WM. Recombinant human interleukin-1 induces meningitis and blood-brain barrier injury in the rat. J Clin Invest 1991;44:1360-66.
35. Brosnan CF, Cannella B, Battistini L, Raine CS. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995;45(S6):S16-S21.
36. Jacobs CA, Baker PE, Roux ER,et al.Experimental autoimmune encephalomyelitis is exacerbated by IL-1 and suppressed by soluble IL-1 receptors. J Immunol 1991;146:2983-89.
37. Waldmann TA The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 1993;14:264-70.
38. Caruso C., Candore G., Cigna D.,et al.Biological significance of soluble IL-2 receptors. Mediators of Inflammation 1993;2:3-21.
39. Chalon MP, Sindic Cjm, Laterre EC Serum and CSF levels of soluble interleukin-2 receptors in MS and other neurological diseases: a reappraisal. Acta Neurol Scand 1993;87:77-82.
40. Harrington L., Affleck G., Urrows S.,et al.Temporal covariation of soluble interleukin-2 receptor levels, daily stress, and disease activity in rheumatoid arthritis. Arthritis Rheum 1993;36: 199-203.